Volume 17, Number 2—February 2011
Dispatch
Comparison of Pandemic (H1N1) 2009 and Seasonal Influenza Viral Loads, Singapore
Table 2
Analysis of pandemic (H1N1) 2009 (HA and NP) and seasonal H3 (MP) viral loads with clinical parameters, Singapore, May–November 2009*
Characteristic | Pandemic influenza |
Seasonal H3 influenza |
||||||
---|---|---|---|---|---|---|---|---|
No. | HA viral load, log10 copies/mL, mean (SD) | NP viral load, log10 copies/mL, mean (SD) | MANOVA p value† | No. | MP viral load, log10 copies/mL, mean (SD) | ANOVA p value | ||
Time from symptom onset, d | <0.0001 | 0.0223 | ||||||
1–2 | 416 | 6.49 (1.44) | 6.49 (1.38) | 53 | 8.12 (1.43) | |||
3–4 | 114 | 6.18 (1.39) | 6.16 (1.40) | 20 | 7.27 (1.31) | |||
5–7 |
48 |
5.33 (1.21) |
5.31 (1.23) |
4 |
6.76 (1.22) |
|||
Age, y | 0.0112‡ | 0.9652‡ | ||||||
0–4 | 69 | 6.46 (1.40) | 6.45 (1.39) | 7 | 7.66 (0.75) | |||
5–14 | 144 | 6.62 (1.36) | 6.65 (1.26) | 11 | 7.93 (1.38) | |||
15–34 | 250 | 6.34 (1.48) | 6.33 (1.43) | 28 | 7.88 (1.66) | |||
35–54 | 72 | 5.85 (1.46) | 5.88 (1.41) | 13 | 7.99 (1.04) | |||
>55 |
43 |
5.88 (1.41) |
5.83 (1.50) |
18 |
7.63 (1.66) |
|||
Sex | 0.3018‡ | 0.3883‡ | ||||||
F | 275 | 6.23 (1.49) | 6.26 (1.38) | 41 | 7.68 (1.52) | |||
M |
303 |
6.42 (1.41) |
6.39 (1.43) |
36 |
8.00 (1.35) |
|||
Comorbidities | 0.9967‡ | 0.0249‡ | ||||||
Yes | 262 | 6.35 (1.49) | 6.35 (1.44) | 22 | 7.23 (1.53) | |||
No |
316 |
6.31 (1.42) |
6.31 (1.39) |
55 |
8.07 (1.35) |
|||
Clinical severity§ | ||||||||
Severe | 23 | 5.97 (1.76) | 5.98 (1.84) | |||||
Hospitalized | 222 | 6.44 (1.49) | 6.42 (1.43) | 7¶ | 7.55 (1.06) | |||
Outpatient | 229 | 6.29 (1.45) | 6.30 (1.40) | 19 | 7.25 (1.54) |
*HA, hemagglutinin; NP, nucleoprotein; MP, matrix protein; MANOVA, multiple analysis of variance; ANOVA, analysis of variance.
†Wilks Lambda statistics.
‡Effect of days from symptom onset adjusted.
§Analysis included patients who sought care during the mitigation phase only (n = 474 for pandemic and n = 26 for H3 seasonal influenzas). Singapore switched from premitigation (i.e., containment) to mitigation management protocols on July 8, 2009, which altered how patient treatment with oseltamivir was initiated. However, this transition does not affect the results shown above because none of the patients were undergoing treatment when these first diagnostic samples were taken.
¶Includes 1 severe case.